These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12949430)

  • 21. A Prospective Audit of Intermittent Anti-Androgen verses Pituitary Blockade Suggests a Bipolar Androgen Type Strategy May Be Safe in Untreated Prostate Cancer.
    Oliver T; Wilson P; Ansell W; Philp T; Chinegwundoh F; Shamash J; Shaw G; Ahmad A
    Urol Int; 2018; 100(2):172-180. PubMed ID: 29275414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of epothilone B analogues ixabepilone and patupilone in hormone-refractory prostate cancer.
    Lee D
    Clin Prostate Cancer; 2004 Sep; 3(2):80-2. PubMed ID: 15479489
    [No Abstract]   [Full Text] [Related]  

  • 23. Complications of Androgen Deprivation Therapy in Men With Prostate Cancer.
    Patil T; Bernard B
    Oncology (Williston Park); 2018 Sep; 32(9):470-4, CV3. PubMed ID: 30248169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Advanced prostatic carcinoma--which hormone therapy when?].
    Studer UE
    Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
    [No Abstract]   [Full Text] [Related]  

  • 25. Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit?
    Park JC; Eisenberger MA
    J Clin Oncol; 2016 Jan; 34(3):211-4. PubMed ID: 26628474
    [No Abstract]   [Full Text] [Related]  

  • 26. Intermittent androgen deprivation.
    Dawson NA
    Curr Oncol Rep; 2000 Sep; 2(5):409-16. PubMed ID: 11122872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of the use of histrelin acetate in the treatment of prostate cancer.
    Crawford ED
    BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
    [No Abstract]   [Full Text] [Related]  

  • 28. Re: Diethylstilbesterol revised: androgen deprivation, osteoporosis and prostate cancer.
    Pitts WR
    J Urol; 2002 Nov; 168(5):2131-2. PubMed ID: 12394735
    [No Abstract]   [Full Text] [Related]  

  • 29. [Intermittent androgen deprivation in advanced prostate cancer: a review].
    Wolff JM
    Aktuelle Urol; 2012 Mar; 43(2):115-20. PubMed ID: 22222751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The question of intermittent hormonal treatment of cancer of the prostate].
    Boca P
    Acta Urol Belg; 1998 May; 66(2):17-20. PubMed ID: 9633121
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.
    Denham JW; Nowitz M; Joseph D; Duchesne G; Spry NA; Lamb DS; Matthews J; Turner S; Atkinson C; Tai KH; Gogna NK; Kenny L; Diamond T; Smart R; Rowan D; Moscato P; Vimieiro R; Woodfield R; Lynch K; Delahunt B; Murray J; D'Este C; McElduff P; Steigler A; Kautto A; Ball J
    BJU Int; 2014 Sep; 114(3):344-53. PubMed ID: 24512527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intermittent androgen blockade in prostatic carcinoma].
    Vachalovský V; Dvorácek J
    Cas Lek Cesk; 2002 Oct; 141(21):669-72. PubMed ID: 12564373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RE: A structured debate: immediate versus deferred androgen suppression in prostate cancer--evidence for deferred treatment.
    Schellhammer PF
    J Urol; 2002 Nov; 168(5):2130-1; author reply 2131. PubMed ID: 12394733
    [No Abstract]   [Full Text] [Related]  

  • 34. Bisphosphonates in prostate cancer: where are we and where should we go?
    Saad F
    J Natl Cancer Inst; 2003 Sep; 95(17):1262-3. PubMed ID: 12953073
    [No Abstract]   [Full Text] [Related]  

  • 35. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].
    Bruchovsky N; Goldenberg SL; Rennie PS; Gleave M
    Urologe A; 1995 Sep; 34(5):389-92. PubMed ID: 7483155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer: management of advanced disease.
    Droz JP; Fléchon A; Terret C
    Ann Oncol; 2002; 13 Suppl 4():89-94. PubMed ID: 12401672
    [No Abstract]   [Full Text] [Related]  

  • 37. Words of wisdom: Re: Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
    Tombal B
    Eur Urol; 2014 May; 65(5):1013-4. PubMed ID: 24646499
    [No Abstract]   [Full Text] [Related]  

  • 38. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
    Wolff JM; Abrahamsson PA; Irani J; da Silva FC
    BJU Int; 2014 Oct; 114(4):476-83. PubMed ID: 24433259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Quality of life of patients with locally-advanced prostate cancer as a criterium of therapeutic effectiveness].
    Kaprin AD; Kostin AA; Tsybul'skiĭ AD
    Vopr Onkol; 2009; 55(3):285-90. PubMed ID: 19670727
    [No Abstract]   [Full Text] [Related]  

  • 40. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.